Treatment Efficacy and Prognostic Factors for Huge HCC Based on Barcelona Clinic Liver Cancer Staging

Abstract

<br/><b>Objective</b>: To explore the most appropriate treatment for patients with hepatocellular cancer (HCC) >10 cmby using the Barcelona Clinic Liver Cancer (BCLC) classification. Materials and <br/><b>Methods</b>: A total of 124 HCCpatients undergoing surgery were selected. Disease-free survival (DFS), overall survival (OS) and prognosticfactors were respectively assessed. <br/><b>Results</b>: This study showed that the cumulative 1-, 3-, 5-year survival rateswere 79.7%, 59.8% and 41.6% in BCLC-A patients, 76.2%, 9.5% and 0% in BCLC-B patients and 44.9%, 0%and 0% in BCLC-C patients, respectively. The 1-, 3-, 5-year DFS rates were 49%, 24.5% and 9.1% in BCLC-Apatients, 7.5%, 0% and 0% in BCLC-B patients, respectively. No BCLC-C patients survived 1 year after surgery.Multivariate analysis indicated that hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepaticmetastasis, curative resection, tumor rupture and pathologic differentiation were independent prognostic factors.<br/><b>Conclusions</b>: Surgery is effective and safe for patients with HCC >10 cm with sufficient hepatic reserve.